MIST Stock Forecast: Milestone Pharmaceuticals, Inc. Price Predictions for 2026-2027

Last close, 20 Nov 2026
$0.37
−6.99% on the day

The median 12-month analyst price target for Milestone Pharmaceuticals, Inc. is $4. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 29 of 100 as at 21 Nov 2026 — in the lower half.

Market cap
$46.2M
Ticker Nerd rank
29/ 100
Median analyst target
$4.00
Analysts covering
7
Revenue$559K
Operating income−$25.6M
Net income−$28.6M
Free cash flow−$22.7M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−28.6%
1M
−48.4%
YTD
−81.6%
1Y
−83.9%
From 52W high
−87.4%
From 52W low
+1.7%
$0.37
$2.95
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores Milestone Pharmaceuticals, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
29/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Revisions
87
Accruals
46
Growth
39
Quality
34
Value
28
Volatility
28
Momentum
8
Issuance
4

Revisions (87): Analysts have, on balance, been raising their forecasts.

Issuance (4): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

MIST stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on MIST, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$1.00$2.00$3.00$4.00$5.00$6.00Jan 26Apr 26Jul 26Oct 26MISTHigh $6.00Median $4.00Low $1.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says7 analysts
6
Buy
1
Hold
0
Sell
$1.00
Low
$4.00
Median
$6.00
High
Recent analyst actionsNewest first

Of the 20 most recent actions, 0 moved their price target up and 4 moved it down.

DateFirmActionRatingTarget
16 Nov 2026HC Wainwright & Co.MaintainsBuy$8.00 → $6.00
16 Nov 2026Piper SandlerMaintainsOverweight$7.00 → $3.00
16 Nov 2026TD CowenMaintainsBuy$8.00 → $5.00
3 Sept 2026HC Wainwright & Co.ReiteratesBuy$8.00
20 Aug 2026Cantor FitzgeraldInitiatesOverweight$3.00
14 May 2026Wells FargoMaintainsOverweight$8.00 → $7.00
6 Jan 2026HC Wainwright & Co.ReiteratesBuy—
16 Dec 2025Wells FargoMaintainsOverweight—
15 Dec 2025HC Wainwright & Co.MaintainsBuy—
15 Dec 2025TD CowenUpgradeBuy—
11 Sept 2025Wells FargoInitiatesOverweight—
5 June 2025HC Wainwright & Co.AssumesBuy$5.00
1 Apr 2025HC Wainwright & Co.MaintainsBuy—
28 Mar 2025HC Wainwright & Co.ReiteratesBuy—
17 Mar 2025HC Wainwright & Co.ReiteratesBuy—
28 Feb 2025HC Wainwright & Co.ReiteratesBuy—
27 Jan 2025HC Wainwright & Co.ReiteratesBuy—
14 Oct 2024HC Wainwright & Co.ReiteratesBuy—
22 Aug 2024HC Wainwright & Co.ReiteratesBuy—
22 Aug 2024Rodman & RenshawInitiatesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for MIST.

Market Radar

This page is one stock. Monday covers all of them.

MIST appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

MIST vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 20 Nov 2026, Milestone Pharmaceuticals, Inc. returned −83.9% against +6.9% for the S&P 500, dividends included.

MIST vs S&P 500, last 12 monthsTotal return, rebased to 100
020406080100120Jan 26Apr 26Jul 26Oct 26MISTS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

MIST analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
0
Analysts cutting
1
Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
—
Price / sales
8.7×

Cheaper than 13% of US stocks

Price / book
2.9×

Cheaper than 32% of US stocks

EV / EBITDA
—
Growth & margins
Revenue growth (YoY)
134.9%

Higher than 94% of US stocks

Earnings growth (YoY)
—
Gross margin
94.3%

Higher than 98% of US stocks

Operating margin
—
Net margin
—
Returns & dividend
Return on equity
−1370.6%

Higher than 1% of US stocks

Return on assets
−45.7%

Higher than 9% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Milestone Pharmaceuticals, Inc. has a market value of $46.2M and an enterprise value of $50.7M.

  • Revenue in the twelve months to 30 June 2026: $2.3M.

  • Net income over the same four quarters: −$84.0M, a −3585.6% net margin.

  • Free cash flow in the twelve months to 30 June 2026: −$61.6M.

  • Shares outstanding: 124.5M.

  • Milestone Pharmaceuticals, Inc. employs 38 people — $62K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 21 Nov 2026

Data provided by Twelve Data

Peers

MIST and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
MISTMilestone Pharmaceuticals, Inc.$46.2M29
TNXPTonix Pharmaceuticals Holding Corp.$46.2M22
HOWLWerewolf Therapeutics, Inc.$46.0M90
RNXTRenovoRx, Inc.$45.5M34
VRCAVerrica Pharmaceuticals, Inc.$47.1M49
APLMApollomics, Inc.$45.3M9
ONCYOncolytics Biotech, Inc.$47.7M38

Take a look at MIST’s peer groups, ranked by the model: healthcare stocks · biotech stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own Milestone Pharmaceuticals, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about MIST

What is the MIST stock price forecast for 2026-2027?

The median 12-month analyst price target for Milestone Pharmaceuticals, Inc. is $4, with estimates ranging from $1 to $6. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is MIST stock a buy right now?

Of the 7 analysts covering Milestone Pharmaceuticals, Inc., 6 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Milestone Pharmaceuticals, Inc. 29 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank MIST?

As at 21 Nov 2026, Milestone Pharmaceuticals, Inc. ranks 29 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Revisions (87 of 100).

Will MIST stock go up?

No one can know that. What the data says: the median 12-month target from 7 analysts is $4, and Ticker Nerd's factor model ranks Milestone Pharmaceuticals, Inc. 29 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the MIST stock forecast for 2030?

No analyst covering Milestone Pharmaceuticals, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for MIST are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $1 to $6 over the next 12 months.

How has MIST stock performed over the past year?

Milestone Pharmaceuticals, Inc. returned -83.9% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Milestone Pharmaceuticals, Inc. do?

Milestone Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing cardiovascular medicines for adults. Milestone Pharmaceuticals Inc.’s lead product, CARDAMYST (etripamil) nasal spray, is designed for the treatment of acute symptomatic episodes of paroxysmal supraventricular tachycardia, with additional development efforts in atrial fibrillation with rapid ventricular rate.

Company

About Milestone Pharmaceuticals, Inc.

Milestone Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing cardiovascular medicines for adults. Milestone Pharmaceuticals Inc.’s lead product, CARDAMYST (etripamil) nasal spray, is designed for the treatment of acute symptomatic episodes of paroxysmal supraventricular tachycardia, with additional development efforts in atrial fibrillation with rapid ventricular rate. The company centers its work on self-administered therapies that can be used outside the emergency department, addressing episodic heart rhythm conditions through a nasal spray delivery format. Based in Montreal, Canada, Milestone Pharmaceuticals Inc. serves the cardiovascular and biotechnology markets through its current product portfolio and ongoing clinical and commercial activities in the United States and Canada.

CEO Mr. Joseph G. Oliveto M.B.A. · 38 employees · Canada · https://www.milestonepharma.com